BSX - Boston Scientific's new clinical trial can impact Abiomed: Raymond James

Abiomed ([[ABMD]] -1.5%) is trading lower after Raymond James noted a potential impact on its biggest revenue generator Impella citing a new clinical trial posted by Boston Scientific ([[BSX]] -0.7%) on the federal clinical trial register.Impella is the only FDA-approved percutaneous heart pump indicated for patients with severe coronary artery disease requiring high-risk percutaneous coronary intervention ((PCI)).The title of the trial is ‘Vortex Temporary Percutaneous, Transvalvular Circulatory Support System (Vortex System).’One of its primary outcome measures is to assess its effectiveness in giving temporary (? 4 hours) support in patients undergoing high-risk percutaneous coronary intervention.It is a notable indication according to the analyst Jayson Bedford who observes the description’s similarity with Abiomed's Impella which generates ~40% of its U.S. revenue from the HC-PCI.For potential tailwinds for Abiomed, Boston Scientific’s entry to the market could accelerate the adoption, the analyst notes despite the apparent competition it has opened.Noting that it is

For further details see:

Boston Scientific’s new clinical trial can impact Abiomed: Raymond James